MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
13.20
-0.24
-1.79%
Opening 13:35 04/23 EDT
OPEN
13.37
PREV CLOSE
13.44
HIGH
13.71
LOW
13.04
VOLUME
43.02K
TURNOVER
0
52 WEEK HIGH
37.75
52 WEEK LOW
8.08
MARKET CAP
279.24M
P/E (TTM)
-2.0106
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ENTA last week (0415-0419)?
Weekly Report · 1d ago
Enanta Pharmaceuticals Insider Sellers Vindicated After 15% Drop
Enanta Pharmaceuticals, Inc. Insiders sold US$325k worth of shares in the last year. The company's market cap plunged by US$54m last week. In the past year, Enanta pharmaceuticals insiders have sold an average of US$9.40 per share. The biggest single sale was by Terry Vance for US$139k. Enanta Pharmaceutical's insiders own about 6.2% of the company. But the company doesn't have any insider purchases over the last 12 months. You can see the insider transactions at Enanta pharmaceuticals in the last 12 months .
Simply Wall St · 5d ago
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Data from the company’s SPRINT study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 in Barcelona, Spain. The poster presentation includes analyses from the double-blind, placebo-controlled Phase 2 clinical trial. Enanta is a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology.
Barchart · 6d ago
Weekly Report: what happened at ENTA last week (0408-0412)?
Weekly Report · 04/15 09:26
Weekly Report: what happened at ENTA last week (0401-0405)?
Weekly Report · 04/08 09:28
Weekly Report: what happened at ENTA last week (0325-0329)?
Weekly Report · 04/01 09:27
Weekly Report: what happened at ENTA last week (0318-0322)?
Weekly Report · 03/25 09:28
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
More
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.